Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Forest Laboratories, Inc. and Glenmark Pharmaceuticals S.A. , a wholly owned subsidiary of Glenmark Pharmaceuticals India announced top–line results from a Phase IIb dose range–finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease. Once–daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.


Today in Dosing...keeping you current

Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09

Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09

Telavancin: A Novel Lipoglycopeptide
Clinical Infectious Diseases, 11/16/09

Today in Drug Trials...keeping you current

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

Today in Other Drugs...keeping you current

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address